SUMO Monoclonal Antibody

Confirm delete?

Zoom

Cat No: 12021

The small ubiquitin like modifier (SUMO) protein is similar in structure and function to ubiquitin. However, SUMO does not typically target proteins for degradation as does ubiquitin.{14288,19512,19511,16072} SUMO is involved with the modification of ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

small ubiquitin like modifier transcriptional regualtion DNA damage repair genomic stability nuclear transport histone modification Smt-3 Smt 3 smo1 smo 1 SUMO-1 SUMO1 SUMO-2 SUMO2 SUMO-3 SUMO3 western blots ELISA

Product Overview:
The small ubiquitin like modifier (SUMO) protein is similar in structure and function to ubiquitin. However, SUMO does not typically target proteins for degradation as does ubiquitin.{14288,19512,19511,16072} SUMO is involved with the modification of a very diverse array of targets.{15532} Proteins involved with transcriptional regulation, DNA damage repair, genomic stability, nuclear transport, and histone modification are all subject to modification by SUMO.{19512,15532,19513,15531} SUMO typically functions by covalently binding to a target protein, followed by regulation of protein:protein and protein:DNA interactions.{19512} The SUMO family of proteins is highly conserved from yeast to human. Invertebrates contain a single SUMO gene (Smt3 in yeast and smo-1 in C. elegans), with three members of SUMO being identified in vertebrates to date (SUMO-1, SUMO-2 and SUMO-3).{21733}

Size	500 µg
Shipping	dry ice
Host	Mouse
Antigen	recombinant yeast Smt3 amino acids 1-97
Clone	3B5
Isotype	IgG1
Application(s)	ELISA and WB
Formulation	500 µg of protein G-purified antibody
Custom Code	3822.19
UNSPSC code	12352203

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.